These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37002733)

  • 1. Prescription Pattern of Glucose-lowering Drugs in Patients with Controlled Type 2 Diabetes Mellitus Attending Dhaka Medical College Hospital.
    Kamrul-Hasan AB; Fardous J; Hasan MJ
    Mymensingh Med J; 2023 Apr; 32(2):277-284. PubMed ID: 37002733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study.
    Kosjerina V; Carstensen B; Jørgensen ME; Brock B; Christensen HR; Rungby J; Andersen GS
    Lancet Healthy Longev; 2021 Sep; 2(9):e561-e570. PubMed ID: 36098008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.
    Herrera Comoglio R; Vidal Guitart X
    Prim Care Diabetes; 2021 Apr; 15(2):323-331. PubMed ID: 33248925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators.
    Kameda T; Kumamaru H; Nishimura S; Kohsaka S; Miyata H
    Curr Med Res Opin; 2020 May; 36(5):749-756. PubMed ID: 32050809
    [No Abstract]   [Full Text] [Related]  

  • 11. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.
    Dankers M; Hek K; Nelissen-Vrancken M; Houweling ST; Mantel-Teeuwisse A; van Dijk L
    Br J Gen Pract; 2022 Jun; 72(719):e430-e436. PubMed ID: 35606162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
    Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
    Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
    Prescrire Int; 2015 May; 24(160):130-5. PubMed ID: 26034806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.
    Luk AOY; Yip TCF; Zhang X; Kong APS; Wong VW; Ma RCW; Wong GL
    BMJ Open; 2021 Oct; 11(10):e052310. PubMed ID: 34670765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Ambulatory Glucose Profile in Precision Medicine in Type 2 Diabetes Mellitus.
    Sidharth S; Aggarwal R; Prakash A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria.
    Yusuff KB; Obe O; Joseph BY
    Pharm World Sci; 2008 Dec; 30(6):876-83. PubMed ID: 18784982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.